Ionis Pharmaceuticals Inc  

(Public, NASDAQ:IONS)   Watch this stock  
Find more results for NASDAQ:ISIS
-0.38 (-0.69%)
After Hours: 55.08 +0.75 (1.38%)
Jul 26, 4:15PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 54.00 - 55.98
52 week 24.58 - 60.01
Open 54.99
Vol / Avg. 1.48M/1.27M
Mkt cap 6.19B
P/E     -
Div/yield     -
EPS -0.17
Shares 123.97M
Beta 3.14
Inst. own 91%
Aug 8, 2017
Q2 2017 Ionis Pharmaceuticals Inc Earnings Call - 11:30AM EDT - Add to calendar
Aug 8, 2017
Q2 2017 Ionis Pharmaceuticals Inc Earnings Release - 9:30AM EDT - Add to calendar
May 24, 2017
Ionis Pharmaceuticals Inc Annual Shareholders Meeting - Webcast
May 17, 2017
Ionis Pharmaceuticals Inc at Bank of America Merrill Lynch Healthcare Conference - Webcast
May 15, 2017
Ionis Pharmaceuticals Inc. Announces Phase 3 NEURO-TTR Conference Call - Webcast
May 9, 2017
Q1 2017 Ionis Pharmaceuticals Inc Earnings Call - Webcast
May 9, 2017
Q1 2017 Ionis Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 3.14% -24.97%
Operating margin 12.68% -14.51%
EBITD margin - -10.76%
Return on average assets 1.39% -9.31%
Return on average equity 9.23% -57.64%
Employees 435 -
CDP Score - -


2855 Gazelle Ct
CARLSBAD, CA 92010-6670
United States - Map
+1-760-9319200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.

Officers and directors

Stanley T. Crooke M.D., Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 71
Bio & Compensation  - Reuters
Elizabeth L. Hougen Chief Financial Officer, Senior Vice President - Finance
Age: 55
Bio & Compensation  - Reuters
B. Lynne Parshall Esq. Chief Operating Officer, Corporate Secretary, Director
Age: 63
Bio & Compensation  - Reuters
Patrick R. O'Neil Esq. Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary
Age: 43
Bio & Compensation  - Reuters
C. Frank Frank Bennett Ph.D. Senior Vice President - Antisense Research
Age: 60
Bio & Compensation  - Reuters
Richard S. Geary Ph.D. Senior Vice President - Development
Age: 59
Bio & Compensation  - Reuters
Brett P. Monia Ph.D. Senior Vice President - Drug Discovery and Corporate Development
Age: 55
Bio & Compensation  - Reuters
Sarah Boyce Chief Business Officer
Age: 45
Bio & Compensation  - Reuters
Spencer R. Berthelsen M.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Breaux B. Castleman Independent Director
Age: 76
Bio & Compensation  - Reuters